BRIEF-Merck says numerical increase in atrial fibrillation and stroke seen in patients taking osteoporosis drug odanacatib

Tue May 6, 2014 9:53am EDT

May 6 (Reuters) - Merck & Co Inc : * Says numerical increase in risk of atrial fibrillation and stroke seen in

patients taking osteoporosis drug odanacatib in late-stage trials * Says "no imbalance" seen in incidence of major cardiovascular events among patients

taking odanacatib and placebo group * Says skin thickening, itching condition seen in 0.2 percent of patients

taking odanacatib * Says 0.1 percent of patients taking odanacatib had femoral shaft fractures,

more than in placebo group

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.